Evidence map›Paper›PMID 30660328›Full record

ArticleNeuropeptides2019

Substance P-mediated cardiac mast cell activation: An in vitro study.

Scott P Levick, Gregory L Brower, Joseph S Janicki

Open access · greenAbstract read
In one paragraph

Article in Neuropeptides, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
2.2field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 30 citations in OpenAlex.

  1. Article
  2. Review
  3. Replacement substance P reduces cardiac fibrosis in monkeys with type 2 diabetes.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2023
    Article
  4. The Role of Leukotriene BJournal of veterinary research · 2023
    Article
  5. Review
  6. Article
  7. Histamine receptors in heart failure.Heart failure reviews · 2022
    Review
  8. Article
  9. Substance P enhances the local activation of NKBMC molecular and cell biology · 2020
    Article
  10. The Role of Mast Cells in IgE-Independent Lung Diseases.Clinical reviews in allergy & immunology · 2020
    Review
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 3 institutions in 2 countries.

Scott P LevickKolling Institute for Medical Research, Royal North Shore Hospital, Australia; Faculty of Medicine and Health, The University of Sydney, Australia. Electronic address: scott.levick@sydney.edu.au.
Gregory L BrowerDepartment of Medical Education, School of Medicine, Texas Tech University Health Sciences Center, United States.
Joseph S JanickiCell Biology and Anatomy, School of Medicine, University of South Carolina, United States.
Texas Tech University · USThe University of Sydney · AUUniversity of South Carolina · US

Funding

Neuro-immune Modulation of Cardiac Mast Cell-Mediated Myocardial RemodelingR00HL093215 · NHLBI · MEDICAL COLLEGE OF WISCONSIN · PI LEVICK, SCOTT P · 2011 to 2013
$709k
Neuro-immune Modulation of Cardiac Mast Cell-Mediated Myocardial RemodelingK99HL093215 · NHLBI · UNIVERSITY OF SOUTH CAROLINA AT COLUMBIA · PI LEVICK, SCOTT P · 2010 to 2010
$90k
NHLBI NIH HHS K99 HL093215NHLBI NIH HHS R00 HL093215
6 · The paper itself

Abstract

The neuropeptide substance P can induce degranulation of cardiac mast cells at high concentrations. Herein, we seek to further understand substance P activation of cardiac mast cells in the context of other neuropeptides as well as modulation by non-neuropeptides. This is important given the increasingly recognized role of both cardiac mast cells and substance P in adverse cardiac remodeling. To address this, we isolated cardiac mast cells and compared their response to substance P as well as other members from the tachykinin family of peptides, including neurokinin A and hemokinin-1. We also tested the ability of other factors to manipulate the cardiac mast cell response to substance P. We found that while neurokinin A did not induce cardiac mast cell degranulation, both substance P and hemokinin-1 induced a concentration-dependent release of histamine; the maximal response to hemokinin-1 was greater than to substance P. Neurokinin-1 receptor blockade prevented substance P-induced histamine release, while only partially attenuating hemokinin-1-induced histamine release. The antioxidant N-acetylcysteine attenuated histamine release in response to hemokinin-1 and had no effect on substance P-induced histamine release. Selective PPAR-γ agonists attenuated histamine release in response to substance P. These data indicate that substance P activates cardiac mast cells via the neurokinin-1 receptor, and that the activation response is different to other tachykinins. That the response to substance P is receptor mediated and can be modulated by activation of other receptors (PPAR-γ), argues that substance P activation of cardiac mast cells has potential biological significance.

Indexed as

AnimalsCell DegranulationHistamineHistamine ReleaseMaleMast CellsMyocardiumPPAR gammaRats, Sprague-DawleyReceptors, Neurokinin-1Substance PVentricular RemodelingHistaminePPAR gammaReceptors, Neurokinin-1Substance P

Identifiers

PMID30660328
PMCPMC7207245
OpenAlexW2910427136

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.